Mitolactol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mitolactol
Accession Number
DB12916
Type
Small Molecule
Groups
Investigational
Description

Mitolactol has been used in trials studying the treatment of Brain and Central Nervous System Tumors.

Structure
Thumb
Synonyms
Not Available
External IDs
NCI-C04795 / NSC-104800
Categories
UNII
LJ2P1SIK8Y
CAS number
10318-26-0
Weight
Average: 307.966
Monoisotopic: 305.910235
Chemical Formula
C6H12Br2O4
InChI Key
VFKZTMPDYBFSTM-GUCUJZIJSA-N
InChI
InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4+,5+,6-
IUPAC Name
(2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mitolactol.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Mitolactol.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Mitolactol.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitolactol.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mitolactol.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Mitolactol.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mitolactol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mitolactol.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Mitolactol.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitolactol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitolactol.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Mitolactol.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Mitolactol.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Mitolactol.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Mitolactol.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mitolactol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitolactol.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Mitolactol.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Mitolactol.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mitolactol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5284380
PubChem Substance
347829064
ChemSpider
4447455
ChEBI
135311
ChEMBL
CHEMBL2104612

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentBrain and Central Nervous System Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility39.7 mg/mLALOGPS
logP-0.44ALOGPS
logP-0.65ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)12.63ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area80.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity50.47 m3·mol-1ChemAxon
Polarizability21.41 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bromohydrins. These are alcohols substituted by a bromine atom at a saturated carbon atom otherwise bearing only hydrogen or hydrocarbyl groups.
Kingdom
Organic compounds
Super Class
Organohalogen compounds
Class
Halohydrins
Sub Class
Bromohydrins
Direct Parent
Bromohydrins
Alternative Parents
Secondary alcohols / Polyols / Organobromides / Hydrocarbon derivatives / Alkyl bromides
Substituents
Secondary alcohol / Bromohydrin / Polyol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Organobromide / Alkyl halide / Alkyl bromide / Alcohol
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:15 / Updated on November 09, 2017 05:14